205 related articles for article (PubMed ID: 12932352)
1. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.
Pashine A; Busch R; Belmares MP; Munning JN; Doebele RC; Buckingham M; Nolan GP; Mellins ED
Immunity; 2003 Aug; 19(2):183-92. PubMed ID: 12932352
[TBL] [Abstract][Full Text] [Related]
2. Determination of the HLA-DM interaction site on HLA-DR molecules.
Doebele RC; Busch R; Scott HM; Pashine A; Mellins ED
Immunity; 2000 Oct; 13(4):517-27. PubMed ID: 11070170
[TBL] [Abstract][Full Text] [Related]
3. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes.
Belmares MP; Busch R; Wucherpfennig KW; McConnell HM; Mellins ED
J Immunol; 2002 Nov; 169(9):5109-17. PubMed ID: 12391227
[TBL] [Abstract][Full Text] [Related]
4. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
5. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.
Vogt AB; Kropshofer H; Moldenhauer G; Hämmerling GJ
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9724-9. PubMed ID: 8790398
[TBL] [Abstract][Full Text] [Related]
7. Intracellular and cell surface heterotypic associations of human leukocyte antigen-DR and human invariant chain.
Triantafilou K; Triantafilou M; Wilson KM; Cherry RJ; Fernandez N
Hum Immunol; 1999 Nov; 60(11):1101-12. PubMed ID: 10600008
[TBL] [Abstract][Full Text] [Related]
8. HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion.
vogt AB; Moldenhauer G; Hämmerling GJ; Kropshofer H
Immunol Lett; 1997 Jun; 57(1-3):209-11. PubMed ID: 9232453
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
10. Conformational variation in structures of classical and non-classical MHCII proteins and functional implications.
Painter CA; Stern LJ
Immunol Rev; 2012 Nov; 250(1):144-57. PubMed ID: 23046127
[TBL] [Abstract][Full Text] [Related]
11. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
Sherman MA; Weber DA; Jensen PE
Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
[TBL] [Abstract][Full Text] [Related]
12. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
Weber DA; Evavold BD; Jensen PE
Science; 1996 Oct; 274(5287):618-20. PubMed ID: 8849454
[TBL] [Abstract][Full Text] [Related]
13. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
14. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.
Kropshofer H; Vogt AB; Thery C; Armandola EA; Li BC; Moldenhauer G; Amigorena S; Hämmerling GJ
EMBO J; 1998 Jun; 17(11):2971-81. PubMed ID: 9606180
[TBL] [Abstract][Full Text] [Related]
15. HLA-DM Stabilizes the Empty MHCII Binding Groove: A Model Using Customized Natural Move Monte Carlo.
Demharter S; Knapp B; Deane C; Minary P
J Chem Inf Model; 2019 Jun; 59(6):2894-2899. PubMed ID: 31070900
[TBL] [Abstract][Full Text] [Related]
16. Enhanced interaction of HLA-DM with HLA-DR in enlarged vacuoles of hereditary and infectious lysosomal diseases.
Lem L; Riethof DA; Scidmore-Carlson M; Griffiths GM; Hackstadt T; Brodsky FM
J Immunol; 1999 Jan; 162(1):523-32. PubMed ID: 9886429
[TBL] [Abstract][Full Text] [Related]
17. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
[TBL] [Abstract][Full Text] [Related]
18. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
[TBL] [Abstract][Full Text] [Related]
19. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
[TBL] [Abstract][Full Text] [Related]
20. HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.
Narayan K; Chou CL; Kim A; Hartman IZ; Dalai S; Khoruzhenko S; Sadegh-Nasseri S
Nat Immunol; 2007 Jan; 8(1):92-100. PubMed ID: 17143275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
